Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.10. | Morgan Stanley Reaffirms Overweight Rating for Silence Therapeutics (NASDAQ:SLN) | 11 | MarketBeat | ||
02.09. | Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data | 3 | Investing.com | ||
30.08. | H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results | 1 | Investing.com | ||
27.08. | Silence Therapeutics plc: Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences | 192 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision... ► Artikel lesen | |
16.08. | Silence Therapeutics stock holds top pick spot and outperform rating at BMO | 1 | Investing.com | ||
16.08. | Analyst Expectations For Silence Therapeutics' Future | 2 | Benzinga.com | ||
16.08. | Silence Therapeutics reports Q2 results | 2 | Seeking Alpha | ||
15.08. | Silence Therapeutics plc - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
15.08. | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 596 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision... ► Artikel lesen | |
15.08. | Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 158 | Business Wire | LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing... ► Artikel lesen | |
27.06. | Silence Therapeutics plc - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
24.06. | Silence Therapeutics Receives $2M Milestone Payment from Hansoh | 2 | Contract Pharma | ||
24.06. | Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma | 2 | Seeking Alpha | ||
24.06. | Silence Therapeutics achieves $2M research milestone payment from Hansoh collaboration | 2 | Seeking Alpha | ||
24.06. | Silence Therapeutics plc: Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration | 172 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples' lives by silencing diseases through precision... ► Artikel lesen | |
20.06. | The Analyst Landscape: 6 Takes On Silence Therapeutics | 2 | Benzinga.com | ||
20.06. | Silence Therapeutics plc - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
20.06. | Silence Therapeutics plc: Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a) | 246 | Business Wire | Study demonstrated highly significant and sustained reductions in Lp(a) to week 48 Data support advancing zerlasiran into phase 3 with 300 mg dose
Silence Therapeutics plc, Nasdaq: SLN ("Silence"... ► Artikel lesen | |
30.05. | Silence Therapeutics plc: Silence Therapeutics to Present at Jefferies Global Healthcare Conference | 260 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision... ► Artikel lesen | |
17.05. | What 7 Analyst Ratings Have To Say About Silence Therapeutics | 2 | Benzinga.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 25,965 | +0,15 % | Pfizer hebt Jahresziele dank starker Quartalsergebnisse an | Pfizer erlebt durch eine starke Nachfrage nach dem COVID-19-Medikament Paxlovid sowie eine solide Performance in anderen Geschäftsbereichen eine positive Umsatzentwicklung. Die angehobene Prognose für... ► Artikel lesen | |
NOVO NORDISK | 103,20 | +0,51 % | Eli Lilly vs. Novo Nordisk: Duell im Kampf gegen die Pfunde | Die beiden Biopharma-Riesen bieten sich ein Kopf-an-Kopf-Rennen um den milliardenschweren Markt für Adipositasmedikamente. DER AKTIONÄR nimmt das Duo unter die Lupe.Mehrere 100 Prozent mit vermeintlich... ► Artikel lesen | |
MERCK KGAA | 154,05 | +1,35 % | JEFFERIES stuft MERCK KGAA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Merck KGaA mit einem Kursziel von 180 Euro auf "Buy" belassen. Analyst Brian Balchin wird in seinem am Dienstag vorliegenden... ► Artikel lesen | |
ELI LILLY | 753,40 | -0,28 % | Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus | ||
VERTEX PHARMACEUTICALS | 436,60 | +0,47 % | Vertex Aktie: Was können Sie jetzt erwarten? | Die Vertex Pharmaceuticals-Aktie verzeichnete am 31. Oktober 2024 einen leichten Kursanstieg von 1,84% auf 438,53 Euro. Trotz der positiven Kursentwicklung in den letzten Wochen, mit einem Zuwachs von... ► Artikel lesen | |
INNOCAN PHARMA | 0,151 | +2,38 % | Unglaubliche Prognose für Montag setzt Innocan Pharma Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
SCHOTT PHARMA | 29,680 | -0,13 % | IPO Night in Frankfurt: Schott Pharma, Talanx und Helsing ausgezeichnet - Lindner und Rhein als Top Speaker dabei | Frankfurt (ots) - Hochkarätige Gäste aus Politik, Wirtschaft und Gesellschaft haben auf der IPO Night in Frankfurt am Main zum zweiten Mal exzellente Leistungen am Kapitalmarkt gewürdigt. Der Award... ► Artikel lesen | |
HAPPY BELLY FOOD GROUP | 0,390 | -1,02 % | Happy Belly Food Group Inc.: Happy Belly Signs Definitive Agreement to Acquire 50% of SALUS Fresh Foods QSR Restaurant Chain | Toronto, Ontario--(Newsfile Corp. - November 1, 2024) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging food brands is pleased... ► Artikel lesen | |
ALNYLAM PHARMACEUTICALS | 254,50 | +0,71 % | Alnylam Pharmaceuticals Inc. Q3 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):Earnings: -$111.57 million in Q3 vs. $147.75 million in the same period last year.
EPS: -$0.87... ► Artikel lesen | |
ALTIMMUNE | 6,315 | +1,58 % | Altimmune, Inc: Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) | IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program... ► Artikel lesen | |
MEDPACE | 296,00 | +0,27 % | Medpace Holdings, Inc. Reports Third Quarter 2024 Results | CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Results
Revenue... ► Artikel lesen | |
DAIICHI SANKYO | 29,980 | +0,81 % | Earnings call: Daiichi Sankyo sees robust growth, raises FY2024 forecast | ||
ELANCO ANIMAL HEALTH | 11,598 | -0,22 % | Elanco Animal Health: Elanco Receives FDA Approval for Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), the Broadest(i) Canine Oral Parasiticide Protection in a Single Monthly Dose | Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms... ► Artikel lesen | |
SHIONOGI | 13,500 | +0,75 % | Shionogi's Xocova effective in preventing symptomatic COVID-19: study | ||
OXFORD BIOMEDICA | 4,680 | +2,18 % | Oxford Biomedica PLC - Total Voting Rights |